TITLE

Renal structure and hypertension in autosomal dominant polycystic kidney disease

AUTHOR(S)
Gabow, Patricia A.; Chapman, Arlene B.; Johnson, Ann M.; Tangel, Douglas J.; Duley, Irene T.; Kaehny, William D.; Manco-Johnson, Michael; Schrier, Robert W.
PUB. DATE
December 1990
SOURCE
Kidney International;Dec1990, Vol. 38 Issue 6, p1177
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hypertension has been reported to occur in 50 to 75 percent of subjects with autosomal dominant polycystic kidney disease (ADPKD) prior to the onset of marked renal insufficiency but concurrent with cystic deformation of the renal parenchyma. The present study was undertaken to examine whether the renal structural abnormalities are greater in hypertensive (HBP) versus normotensive (NBF) male and female patients with ADPKD who were matched within gender groups for age, body surface area, serum creatinine concentration (males HBP 1.2 ± 0.02 vs. NBP 1.1 ± 0.03 mg/dl, NS; females HBP 0.9 ± 0.03 vs. NBP 0.9 ± 0.02 mg/dl, NS) and creatinine clearance (males HBP 100 ± 3 vs. NBP 108 ± 3 ml/min/l.73 m², NS; females HBF 97 ± 3 vs. NBP 96 ± 2 ml/min/1.73 m², NS). Renal volume was significantly greater in the HBP compared to the NBP group (males HBP 624 ± 47 vs. NBP 390 ± 43 cm³, P < 0.0005; females HBP 466 ± 32 vs. NBP 338 ± 24 cm³, P < 0.002). Since increased renal volume is due to increased cysts, the results indicate that the early high incidence of hypertension in ADPKD correlates with the renal structural abnormalities in this disorder.
ACCESSION #
17656919

 

Related Articles

  • Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Erickson, Kevin F.; Chertow, Glenn M.; Goldhaber-Fiebert, I Jeremy D. // Annals of Internal Medicine;9/17/2013, Vol. 159 Issue 6, p382 

    Background: In the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function. Objective: To determine how the benefits of tolvaptan seen in...

  • Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Bukanov, Nikolay O.; Smith, Laurie A.; Klinger, Katherine W.; Ledbetter, Steven R.; Ibraghimov-Beskrovnaya, Oxana // Nature;12/14/2006, Vol. 444 Issue 7121, p949 

    Polycystic kidney diseases (PKDs) are primarily characterized by the growth of fluid-filled cysts in renal tubules leading to end-stage renal disease. Mutations in the PKD1 or PKD2 genes lead to autosomal dominant PKD (ADPKD), a slowly developing adult form. Autosomal recessive polycystic kidney...

  • Genetic analysis (PKD2) of autosomal dominant polycystic kidney disease. Gómez, P. Fraile; Moro, E. Corral; García-Cosmes, P.; González Sarmiento, R.; Tabernero^Romo, J. M. // Nefrologia;Dec2009, Vol. 29 Issue 6, p562 

    Autosomal dominant polycystic kidney disease is a multiorganic hereditary disorder. It is responsible for 7-10% of cases of end stage renal failure. It is caused by mutations in the genes PKD1 and PKD2. Both polycystic kidney disease's forms have a pathogeny and similar clinic, but in the...

  • Genetic and Gender Risk Factors for Patients with ADPKD.  // Kidney;Mar/Apr98, Vol. 7 Issue 2, p56 

    Discusses the abstract of the article 'Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease,' by A.M. Johnson and P.A. Gabow, published in the 1997 issue of the 'Journal of the American Society of Nephrology.'

  • Diverticular Disease in Patients with Chronic Renal Failure Due to Polycystic Kidney Disease. Scheff, Robert T.; Zuckerman, Gary; Harter, Herschel; Delmez, James; Koehler, Robert // Annals of Internal Medicine;Feb80 Part 1, Vol. 92 Issue 2, p202 

    Provides information on diverticular disease in patients with chronic renal failure due to polycystic kidney disease. Association of diverticulitis with polycystic kidney disease; Occurrence of diverticulosis; Clinical course of patients with polycystic kidney disease and diverticulitis.

  • Pathway to polycystic kidney disease.  // Journal of Clinical Investigation;Oct2010, Vol. 120 Issue 10, p3403 

    The article reports that hyperactivation of the mammalian target of rapamycin (mTOR) leads to autosomal dominant polycystic kidney disease (ADPKD) which in turn also leads to cystogenesis and chronic renal failure.

  • Pseudodominant inheritance of nephronophthisis caused by a homozygous NPHP1 deletion. Hoefele, Julia; Nayir, Ahmet; Chaki, Moumita; Imm, Anita; Allen, Susan; Otto, Edgar; Hildebrandt, Friedhelm // Pediatric Nephrology;Jun2011, Vol. 26 Issue 6, p967 

    Nephronophthisis (NPHP) is an autosomal recessive kidney disease characterized by tubular basement membrane disruption, interstitial infiltration, and tubular cysts. NPHP leads to end-stage renal failure (ESRD) in the first three decades of life and is the most frequent genetic cause of chronic...

  • Hypertension in autosomal dominant polycystic kidney disease. Chapman, Arlene B.; Gabow, Patricia A. // Kidney International Supplement;Oct1997, Issue 61, pS-71 

    Reports on the involvement of hypertension in autosomal dominant polycystic kidney disease. Characterization of the disease by renal cyst expansion replacing normal renal tissue; Effect of hypertension in the overall survival of the patient suffering from the disease; Presence of...

  • Hypertension and Systemic Disease.  // Kidney;Mar/Apr2004, Vol. 13 Issue 2, p68 

    Discusses several medical studies on hypertension and systemic disease. Assessment of patients with Wegener's granulomatosis or microscopic polyangiitis with biopsy-confirmed renal involvement; Study of the progression of renal insufficiency in type 2 diabetes with and without...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics